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license (http://creativequires a profound mechanistic understanding of the disease. Here, we propose a model-driven
approach supporting the systematic identification of putative disease mechanisms.
Methods: We have created a model for AD and a corresponding model for the normal physiology of
neurons using biological expression language to systematically model causal and correlative relation-
ships between biomolecules, pathways, and clinical readouts. Through model-model comparison we
identify “chains of causal relationships” that lead to new insights into putative disease mechanisms.
Results: Using differential analysis of our models we identified a new mechanism explaining the ef-
fect of amyloid-beta on apoptosis via both the neurotrophic tyrosine kinase receptor, type 2 and nerve
growth factor receptor branches of the neurotrophin signaling pathway. We also provide the example
of a model-guided interpretation of genetic variation data for a comorbidity analysis between AD and
type 2 diabetes mellitus.
Discussion: The two computable, literature-based models introduced here provide a powerful
framework for the generation and validation of rational, testable hypotheses across disease areas.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; OpenBEL; APP; Alzheimer’s disease model; Neurotrophin signaling; Type 2 diabetesmellitus1. Introduction
Difficulties with the diagnosis of Alzheimer’s disease
(AD) and the absence of disease-modifying treatments for
AD remain among the great challenges in biomedicine that
need to be addressed in the 21st century. Recent disap-
pointing results of Alzheimer’s treatment trials reaffirm
that pathogenic mechanisms underlying dementia are more
complex than previously thought [1]. Given the obvious
complexity of the AD pathology, an important questional interests: The authors declare no competing finan-
uthor. Tel.: 149-2241-14-2802; Fax: 149-2241-14-
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).that arises is whether current knowledge provides a way for-
ward to better understand the underlying pathological
pathways.
It has been long hypothesized that the deposition of
amyloid-beta peptide in the brain triggers a cascade of mo-
lecular events that consequently lead to AD dementia. The
amyloid hypothesis represents the mainstream scientific
opinion and knowledge on the cause and progression of
AD, despite the growing skepticism surrounding this hy-
pothesis [1]. The amyloid-beta protein also plays normal
physiologic roles, for example, as protein hormones [2].
Given the amount of accumulated knowledge on both
normal and abnormal function of amyloid, which remains
scattered in the form of free text and representations in
various pathway databases, in silico modeling methods pro-
vide a means of aggregating and presenting this informationimer’s Association. This is an open access article under the CC BY-NC-ND
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processes and pathways involved in the pathogenesis of
AD have been collectively represented in the form of the
AlzPathway map [3]. However, to be useful and supportive
for drug and biomarker discovery efforts, such disease
maps need to go beyond the pure representation of pathway
information as cartoons, which suffer from missing biolog-
ical entities (such as Single Nucleotide Polymorphisms
[SNPs]) and difficulties in relational representation. Unfor-
tunately, current AD models do not capture the dynamic na-
ture of the disease (e.g. staging) and because of the lack of
time course gene expression data on AD in humans, these
models do not permit to go beyond the simple overlay of
expression snapshots obtained from post-mortem brains.
Future modeling approaches should thus support the auto-
matic reasoning of interlinked molecules and processes. We
argue that a computer-processable disease model should be
readily amenable to computational reasoning for disease
mechanism discovery based on the identification of cause-
and-effect regulatory effects, thus linking upstream causal en-
tities to downstream bioclinical effects. Furthermore, in the
absence of healthy state models that represent normal cellular
processes, any attempt to derive mechanistic interpretations
of disease is inconclusive. Thus, disease mechanism discov-
ery requires the conversion of descriptive knowledge into
computer-processable cause-and-effect models and mecha-
nistic interpretation should be addressed by the differential
analysis of normal and abnormal processes.
We address these requirements by constructing two cause-
and-effect computer-processable models for pathophysiolog-
ical processes associated with AD and their healthy state
analogs based on the Biological Expression Language (BEL;
http://www.openbel.org/). BEL integrates literature-derived
“cause and effect” relationships into network models, which
can be subjected to causal analysis using quantitative data
such as gene expression. The models developed here not
only represent a comprehensive view on the core established
pathways involved in amyloid processing but also cover a
broad spectrum of events that lead to clinical readouts often
seen in AD patients, such as neuroinflammatory processes.
Moreover, the healthy and disease state models provide a
means for mechanistic differential analysis through which
causal pathogenic pathways can be identified.2. Methods
2.1. Data collection and human APP BEL model building
The scientific knowledge of physiological functions
(normal) and pathological actions (diseased) of amyloid pre-
cursor protein (APP) processing were acquired from AD-
related articles, reviews, and databases. First, 37 pathway
cartoons were collected from pathway databases (such as
Kyoto Encyclopedia of Genes and Genomes [KEGG]
(http://www.genome.jp/kegg/), Reactome (http://www.
reactome.org/PathwayBrowser/), and BioCarta (http://www.biocarta.com/genes/index.asp)). Second, using SCAI-
View [4] we retrieved a list of 4124 genes, reported to be
linked to pathology of AD, of which the top 50 genes were
selected based on their relevancy to the query. Documents
tagged for these genes were manually filtered for normal
(64 documents) and disease (295 documents) states. Rela-
tionships reported in these documents were encoded in
BEL language v1.0 and used to build the APP BEL models.
Furthermore, documents related to top 10 AD related genes
were obtained from the AlzGene Database [5]. The APP
BEL models were validated for correct syntax and compiled
using the OpenBELFramework v2.0, omitting Phase III
network augmentation. The models were visualized using
Cytoscape and queried using the OpenBEL Knowledge As-
sembly Model (KAM) Navigator Cytoscape plug-in (https://
github.com/OpenBEL/Cytoscape-Plugins).2.2. Comparison of the normal and disease state models
To identify differential pathways, which are specifically
present in the disease state model, the two APP models
were compared using the Cytoscape plug-in “advanced
network analysis” [6].2.3. GSEA using MSig database
The “Compute Overlaps” tool available via MSigDB
(http://www.broadinstitute.org/gsea/msigdb/help_annotatio
ns.jsp#overlap) was used to identify enriched pathways in
the BEL models and the AlzPathway map, using the canon-
ical pathways collection of gene sets (MSig database v4.0
updated May 31, 2013). This was used to identify the com-
mon canonical pathways between Normal and Disease state
BEL models and to revalidate the specificity of models with
AD context and to compare it with the existing AlzPathway
model. Three canonical pathway data sets were used to
compute overlaps; BioCarta, Reactome, and KEGG. Anal-
ysis was done using the entire gene list of both (normal
and diseased) models and AlzPathway. From the BEL
models, we have extracted all the genes/proteins/RNA
names (referenced by HUGO Gene Nomenclature Commit-
tee [HGNC] namespace) and given as input for computing
overlaps. For further analysis, we have selected the top
ranked pathways by the number of genes with the highest
P-value and FDR-q value by Gene Set Enrichment Analysis
(GSEA) analysis. From the common pathways, the overlap-
ping genes were identified for both disease and normal BEL
models and identified how these pathways differentiate the
normal and diseased states.
2.3.1. SNP analysis for comorbidity
Genetic variants (SNPs) for Alzheimer disease (AD)
and genes of APP-related pathways were collected from
PubMed and genome-wide association studies (GWAS)
databases in which SNPs were identified for AD and
genes of APP-related pathways. Using GWAS databases,
A.T. Kodamullil et al. / Alzheimer’s & Dementia 11 (2015) 1329-1339 1331more than 9000 SNPs for AD with the P-value threshold
,1023 were collected. Of this, 96 SNPs associated with
47 genes were encoded in the APP-disease model. SNPs
were prioritized according to their functional effect on
the gene/protein in the disease context based on scores
referring to the RegulomeDB database (http://regulome.
stanford.edu/index) and experimental evidence for their
position in a chromatin state was obtained from the Chro-
MoS web tool [7].3. Results
3.1. APP biology models representing normal versus
disease processes in human brain
Following the workflow illustrated in Fig. 1, 295 articles
were found to contain essential information on APP
processing under disease condition in human brain and
were used to build the so-called “APP-Disease model”; simi-
larly, 64 articles were used to construct the “APP-Normal
model” representing the analogous normal processing of
APP in neurons (Fig. 2). This imbalance between the number
of articles is reflecting the publication bias toward APP in the
disease context as compared with reports on its normal bio-
logical role. Although we are aware of this bias, we aimed at
the maximum coverage of causal and correlative statements
that can be encoded in BEL. Consequently, the models
we present here have grown way beyond this well-
characterized APP pathophysiological endpoint and now
include the vast majority of AD associated processes and
pathways. As a result, the models encoded in BEL consist
of 701 nodes for “APP-Normal” and 1314 nodes for “APP-
Disease”. There are 920 BEL knowledge statements config-
uring the APP-Normal model and 2087 BEL statements
supporting the APP-Disease model. The total numbers of in-
teractions (edges) in normal and disease models are 1416
and 2935, respectively.
The APP BEL models (normal and disease) were
compared with the previously published AlzPathway
model in terms of information coverage [3]. A comparison
among all three models is shown in Supplementary
Table 1. To investigate functional similarities and differ-
ences in content, a comparative pathway analysis was per-
formed with the AlzPathway model using pathway
enrichment analysis (see Methods) with the canonical path-
ways in the MSig database [9] (Supplementary Table 2).
The literature supporting the role of unique pathways of
APP-Disease model indicates that these unique pathways
form the core of hypotheses describing the pathology of
AD (Supplementary Table 3)
3.2. Differential analysis of APP-Normal and APP-
Disease models for identification of causal events
The differential model analysis aims to identify patho-
physiological mechanisms underlying disease in compari-
son to the normal baseline function. We developed astrategy for differential model analysis that normalizes be-
tween the two models at the level of common, overlapping
processes and pathways.
After the alignment of two APP models, we identified the
disease-specific parts of the APP-Disease model by subtrac-
tion of the nodes and edges shared by bothmodels. The result-
ing “delta” model was subjected to pathway enrichment
analysis, which resulted in the identification of several path-
ways enriched in the portion of the model that is unique to dis-
ease, for example, the neurotrophin signaling pathway,
mitogen-activated protein kinase (MAPK) signaling pathway,
and signaling by nerve growth factor (NGF). The identifica-
tion of these pathways provides a starting point for the gener-
ation of mechanistic hypotheses. The integration of additional
information from high-throughput data sources (e.g. GWAS
data; gene expression data) and scientific literature not used
to build the BEL model (e.g. patent literature) provide inde-
pendent evidence for the relevance of a putative diseasemech-
anism identified through differential model analysis.
Because the neurotrophin signaling pathway was among
the top identified, disease-associated pathways, we investi-
gated this pathway in more detail. In our BEL models, we
identified four key regulators of the neurotrophin signaling
cascade as described in the KEGG neurotrophin pathway,
namely NTRK2 (neurotrophic tyrosine kinase receptor,
type 2), BDNF (brain-derived neurotrophic factor), nerve
growth factor receptor, and NGF. However, the differential
model analysis reveals that the mode of interaction among
these four proteins drastically differs between the normal
and disease states. Accordingly, these proteins control two
branches of the neurotrophin pathway, which regulate the
balance between two possible biological outcomes, namely
neuron survival versus apoptosis (Fig. 3).
The neurotrophic protein BDNF and its receptor NTRK2
are involved in neuron differentiation and growth. In the
normal state, ubiquitin carboxyl-terminal esterase L1
(UCHL1), a deubiquinating enzyme that controls BDNF-
mediated retrograde transport, activates BDNF, and in-
creases the binding of BDNF to its receptor NTRK2, thereby
promoting neuronal development and homeostasis. In
contrast, under AD conditions, amyloid-beta prevents the
binding of BDNF to NTRK2 receptor, thereby blocking
BDNF-NTRK2 downstream signaling. This blockade leads
to the repression of neuron survival, differentiation, and
growth, so that abnormal APP processing and amyloid-
beta production has been experimentally shown to attenuate
BDNF-NTRK2 signaling [10]. UCHL1 activity is repressed
by amyloid-beta, which in turn impairs BDNF-NTRK2-
mediated downstream signaling, leading to diminished syn-
aptic plasticity and neuronal survival [11]. Our BEL models
also shed light on a second pathophysiology mechanism of
two other proteins involved in neurotrophin signaling:
NGFR and NGF. In the normal state, the NGF protein binds
to NGFR resulting in NGFR polyubiquitination. Ubiquiti-
nated NGFR binds to inhibitor of kappa light polypeptide
gene enhancer in B-cells, kinase beta (IKBKB) and activates
Fig. 1. Schematic representation of the model construction and analysis workflow: Two amyloid precursor protein (APP) models were built using the scientific
knowledge present in the scientific literature, databases, pathway cartoons, and genomic databases. The twomodels represent the normal neuron physiology and
the diseased state physiology. The initial models have undergone an enrichment through Reverse Causal Reasoning (RCR) analysis [8]. Differential model com-
parison based on gene set enrichment led to the generation of two hypotheses, which were investigated further in silico and are supported by additional, inde-
pendent evidence.
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B-cells 1 (NFKB1), which promotes neuronal cell survival
[11]. In the disease state, amyloid beta peptides competi-
tively bind to the NGFR and inhibit the binding of NGF, re-
sulting in increased cell death [13,14].
An exhaustive search of patent and nonpatent literature
for further evidence supporting the mechanism of compet-
itive blocking of the NGF receptor through APP peptides
revealed that although the literature supports the inhibi-
tion of BDNF signaling by APP and the induction ofNGFR-mediated cell death by APP, separately, the
embedding of the competitive binding of NGF and APP
peptides in the context of the model shown in Fig. 3
brings these observations together as a novel, cohesive
disease mechanism. Further supportive evidence comes
from the patent literature [15]. Accordingly, the occur-
rence of a mutation from lysine to alanine at position
34 of the NGF amino acid sequence has been detected
that results in binding mutant NGF molecule to NGFR
with 50% lower affinity. Interestingly, the patent reports
Fig. 2. Amyloid precursor protein (APP) biological expression language (BEL) models: The first image (A) represents APP-Disease model and second image
(B) represents APP-Normal model. The observation that the APP-Normal model is sparse but the APP-Disease is denser reflect the bias toward the research in
pathology, as compared with normal physiology of APP in the human brain.
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“lysine-glycine-alanine” in the amyloid peptide that pro-
vides a binding site for NGFR, thus creating a competitive
binding capacity for the amyloid peptide.
3.3. Systematic aggregation of evidence in support of the
amyloid-mediated neurotrophin switch hypothesis
The putative amyloid-mediated switch mechanism iden-
tified through differential model analysis of the neurotrophin
signaling pathway is based on qualitative information. To
further support the mechanism of action exerted by amyloid
beta in the neurotrophin signaling pathway, we systemati-
cally harvested and screened independent pieces of evidence
from experimental databases containing data sets on
knockout mouse models and miRNAs. For four key regula-
tors in the neurotrophin signaling pathway (BDNF, NGF,
NGFR, and NTRK2), knockout mice were identified in the
Mouse Genome Informatics database [12] and this provides
supportive evidence for the proposed amyloid-switch mech-
anism (Supplementary Table 4).
We also systematically investigated reports on miRNAs
that regulate the genes in the neurotrophin pathway. Indeed,
several miRNA studies provide supportive evidence for a
key role of members of the neurotrophin pathway in early
decision making on neuron survival [16,17] (see
Supplementary Table 5).
3.3.1. Biomarker-guided validation of the amyloid-
mediated neurotrophin switch hypothesis
Mentions of potential biomarkers in the literature can be
used for biomarker-guided pathway analysis [18]. Wetherefore extracted mentions of potential biomarker func-
tions of BDNF, NTRK2, NGF, and NGFR from the litera-
ture (Supplementary Table 6). Mapping these evidences for
expressed biomarkers to the neurotrophin pathway clearly
supports the amyloid-dependent switch mechanism hy-
pothesis (Fig. 3). The coordinated decrease in the levels
of NGF and increased expression of NGFR protein, on
one hand, and consistent decrease in levels of BDNF-
NTRK2 complex, on the other hand, is aligned with our
hypothesis and can be mechanistically explained by the
model. In addition, the decreased expression of BDNF
and NTRK2 in synergy with the inhibitory effect of amy-
loid beta on UCHL1 leads to “switching” the entire
pathway from its normal state with neuroprotective effect
to the disease state with a strong trend toward neuron
apoptosis.
3.4. Inclusion of genome variation information in causal
models
The addition of information on genetic variation to BEL
models can support the generation of new hypotheses and
analyze their mechanistic link to comorbidities of AD such
as diabetes. The enrichment analysis of our models earlier
indicated that insulin signaling pathway is among signifi-
cantly enriched pathways connected to the APP processing
(see Supplementary Table 2). Accumulated evidence suggests
that type 2 diabetes mellitus (T2DM) is a strong risk factor for
AD, as shown by Akomolafe (2006) [19] and patients treated
with insulin were at highest risk of dementia [20].
Consistent with these findings, analysis of APP-Normal
and APP-Disease models revealed that some interactions in
Fig. 3. Molecular decision-makingmechanism linked to the neurotrophin signaling pathway between Normal and Disease states: The nodes and edges shown in
green color represent the normal pathway. The red color indicates the perturbation of the neurotrophin pathway under Alzheimer’s disease diseased state con-
ditions. The node act represents activity of the protein and (U) represents the ubiquitination of the protein. The black colored arrows (up and down) indicate over-
or underexpression of the nodes in diseased state from the biomarker guided validation.
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such as amyloid beta peptides (see Supplementary Table 2).
We have identified 12 functionally relevant SNPs linked to
ADandT2DMand associated themwith threegenes (clusterin
[CLU], serine/threonine kinase 11 [STK11], and phosphatidy-
linositol binding clathrin assembly protein [PICALM]) in the
APP-Diseased BEL model (Supplementary Table 7). Two of
the three genes (CLU and STK11) could be integrated with
prior knowledge to build a hypothesis (Fig. 4).
3.4.1. Model-guided interpretation of genetic variation
data by inferring chains of causation
The comorbidity model shown in Fig. 4 reveals the
possible causative effects of genetic variants on the mech-
anistic association of T2DM with AD. In a recent GWAS
study on AD, CLU intronic SNPs were found to be associ-
ated with the disease [4,21,22]. Clusterin is a transport
protein and has a role in helping the clearance of
amyloid-beta by transporting it through the blood-brain
barrier [23]. The risk variant rs9331888 (with allele G)
associated with the CLU gene increases the quantity of a
CLU isoform in AD, which induces apoptosis [24] and
may contribute to the accumulation of amyloid beta in
AD (Fig. 5). A study that quantified levels of clusterin iso-
forms showed a decrease in secreted soluble CLU in pro-
dromal Alzheimer brain and a significant increase in
intracellular CLU [25]. Furthermore, in a proteomic anal-
ysis of human hippocampal tissues from AD brains and
age-matched control brains, it was confirmed that an iso-
form of CLU is upregulated in AD cases [26]. Moreover,AD patients have a higher expression of CLU mRNA
and its concentration is positively linked to programmed
cell death or apoptosis [27]. In line with these observa-
tions, expression quantitative trait loci (eQTL) analysis
has shown that CLU is overexpressed in AD [28]. It is
possibly linked to fibrillar amyloid-beta and apoptotic
mechanisms in neurodegenerative diseases [29]. One of
the SNPs (rs1532278) in the CLU gene is also associated
to T2DM in GWAS analyses of diabetes patients; the
amount of CLU is also significantly increased in the serum
of T2DM patients, which is correlating with blood glucose
levels [29]. It has been hypothesized that this SNP is linked
to T2DM through insulin resistance and impairment of in-
sulin secretion.
Similarly, genetic variants of STK11 have been linked to
T2DM and also to AD in GWAS studies [39,40]. In mouse
models, the deletion of this gene is linked to the inhibition
of axon branching [41]. According to GWAS studies, two in-
tronic SNPs in the STK11 gene are associated with AD [39].
Moreover, two intronic SNPs of STK11 are also associated
with T2DM. The expression of STK11 in liver seems to be
required to lower blood glucose and its deficiency upregulates
gluconeogenesis. Additionally, targeted STK11 deletion in
liver leads to hyperglycemia [42] (Fig. 6). Furthermore,
mouse models lacking S6K1 (C57BL/6J) display enhanced
insulin sensitivity [7]. The dysfunction of STK11 gene may
also contribute to the accumulation of amyloid beta via the
overactivation of mTOR and inhibition of autophagy. Gene
expression studies show that STK11 is downregulated in
AD [43]. Finally, the relevance of the regulatory and causal
Fig. 4. Comorbidity association of Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM) by genetic variants of clusterin (CLU) and serine/threonine
kinase 11 (STK11) genes: In the normal state (green color edges), insulin protein binds to its receptor insulin receptor and this binding event activates INSR
through phosphorylation [30]. The activated INSR binds to insulin-like growth factor 1 (IGF1) and activates insulin receptor substrate 1 (IRS1) [31]. Activated
IRS1 activates the phosphoinositol signaling system which activates protein kinase B (AKT) signaling and controls glycogenesis. Activated INSR binding to
IGF1 also activates Src homology 2 domain containing protein (SHC) and thereby activates the MAPK signaling pathway [32]. In the disease state (red color
edges), CLU promotes neuron apoptosis [27]. Amyloid beta peptides bind to INSR, effectively preventing activation of INSR by insulin. As a consequence,
through inactivation of the phosphoinositol signaling system, AKT signaling and mitogen-activated protein kinase (MAPK) signaling pathways, binding of
APP peptides suppresses the insulin signaling pathway [33]. The CLU single nucleotide polymorphisms (SNPs) are associated with an increased production
of amyloid beta peptides and the CLU variants increase the risk of T2DMby primarily inducing the insulin resistance and secondly by decreasing the production
of insulin [34]. In the case of insulin resistance, the amount of INS is increased due to its accumulation in the blood [35]. Normally under the condition of energy
stress, STK11 activates adenosine monophosphate-activated protein kinase (AMPK) by phosphorylation and AMPK activation decreases Mechanistic target of
rapamycin serine/threonine kinase (mTOR) signaling activity, thereby helping degradation of b-amyloid. In T2DM, the SNP rs8111699, which maps to the
enhancer region of the STK11 gene, is influencing insulin sensitivity [35]. The other SNP (rs741765) is located in the insulator region, which may block
the interaction between the enhancer and promoter of the gene, resulting in downregulation of the STK11 gene [36]. Deficiency and dysfunction of STK11
inhibits the AMPK phosphorylation, thereby reducing the activity of AMPK [37], which hyper-activates mTOR signaling in AD [38]. Moreover, in T2DM,
hyperactivation of mTOR signaling inhibits IRS1 via activation of S6K1 and the IRS1 inhibition leads to insulin resistance (linking the STK11 causal graph
to the CLU graph), which leads to increase in INS and glucose in blood. The black colored arrows (up and down) indicate over- or underexpression of the nodes
in diseased state; while dotted arrows are inferring the possible effect of genetic variants.
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antidiabetic drug known as metformin, which is used to acti-
vate AMPK (Adenosine monophosphate-activated protein ki-
nase) phosphorylation and probably may repress and delay
the appearance of AD pathology [44].4. Discussion
There is an unmet need for strategies to model and
identify potential disease-initiating events/mechanisms
in the absence of both sufficient data (which makes
data-driven approaches impossible) and models for early
Neurodegenerative disease (NDD) initiation (which
makes a simple cause-effect analysis very difficult). We
believe that complex, idiopathic diseases cannot be ad-
dressed by the established routes of molecular biologyexperimentation alone, as neurodegeneration works in
the context of an entire organ and the pathology can
only be studied in the organ context. Model-driven ap-
proaches are a way to capture the collective knowledge
about disease processes and allow for a comparison at
systems level.
The results of this study demonstrate that encoding
relevant knowledge into causal relationship models con-
fers enhanced interpretation power that is well-suited for
hypothesis generation. BEL models of APP processing
represent a broad coverage of the molecular knowledge
on the pathological events underlying AD while preser-
ving sensitivity (by inclusion of various biological path-
ways linked to the core pathology), specificity (by
inclusion of species- and disease-specific information),
and context (by inclusion of almost all types of biological
Fig. 5. Evidence-based interpretation of CLUgenetic variation effect: The flowchart shows themajor evidences from the biological expression language (BEL)-
Model that support the mechanistic interpretation of genetic variants (single nucleotide polymorphisms) of clusterin (CLU) and links these mechanisms with
disease etiology of late-onset Alzheimer’s disease (LOAD) and type-2-diabetes T2DM). In diseased state, CLU is inducing the increased production of amyloid
beta peptides, which is binding to insulin receptor (INSR) and inhibits the insulin-signaling pathway. Moreover, CLU is associated with an increasing risk for
T2DM primarily by inducing insulin resistance and secondarily by decreasing insulin secretion. It is also increasing neuron apoptosis in diseased state.
A.T. Kodamullil et al. / Alzheimer’s & Dementia 11 (2015) 1329-13391336entities). Our approach overcomes the general problem of
missing values, low reproducibility, and static representa-
tion with microarray gene expression data so that differ-
entially expressed genes detected for the same diseaseFig. 6. Evidence-based interpretation of STK11 genetic variation effect: Cartoon-l
language (BEL) models that associate genetic variants (SNPs) of STK11/LKB1 gen
type-2-diabetes (LOAD and T2DM).are often highly inconsistent and may even fail to include
genes representing key causal mechanisms [45]. For
instance, the functional role of neurotrophin signaling
pathway in pathology of AD could be completely ignoredike representation flowchart of evidence encoded in the biological expression
e to the putative disease etiology of late-onset Alzheimer’s disease (AD) and
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and NGRF were considered. In contrast, the power to
detect this mechanism was remarkably increased when
knowledge-based BEL models were used as the integra-
tive platform for expression data.
We are of course aware of the fact that differences be-
tween the two models we generated could either reflect
true pathomechanisms that differentiate the healthy and
the diseased state, or—in the most trivial case—could reflect
differences in the research published so far on a certain
biology. We therefore emphasize that the differential model
analysis is a way to generate hypotheses on possible patho-
mechanisms, but does not provide any proof for their true ex-
istence. Additional, independent evidence (e.g. SNP data
that support the notion of an important, putative disease
mechanism) and classical model validation strategies using
independent data sets (e.g. RNAseq data) will help us to
rapidly identify those hypotheses that merit an in-depth anal-
ysis, including experimental validation in appropriate exper-
imental systems.
Our differential analysis of normal and disease states in
AD and the additional supporting information provided
evidence for the key role of amyloid-beta in switching
the neurotrophin signaling pathway between cell survival
and cell death. Retrospectively, we found an elegant study
by Matrone et al. (2009), which lends empirical support to
the role of amyloid-beta in switching from prosurvival to
proapoptotic activity of the neurotrophin pathway [46].
Consistent with these results and as preclinical support
for the previously mentioned hypothesis, the administra-
tion of small molecule BDNF mimetics or injection of
NGF to mice models of AD has been clearly shown to
result in rescue from cell death and the promotion of
neuronal survival [47].
Enriched context of the APP BEL-based models with
SNP data leveraged the interpretation power and allowed
for linking causal effects of genetic variants to down-
stream molecular pathways and biological phenotypes,
as exemplified for insulin resistance under AD conditions.
Indeed, encoding SNPs in BEL models allows for linking
SNP-associated effects to a larger functional context
including biological pathways. On one hand, for most of
known and statistically significant SNPs in AD GWAS re-
sults including CLU, the mode of action is not well under-
stood but the presented BEL model in this study explains
how intronic variants of CLU may increase the risk of AD
through insulin resistance and increasing prevalence of
T2DM. On the other hand, rare regulatory variants such
as on STK11, which reside on noncoding regions of genes
and are difficult to detect, have been shown to be causal
for several monogenic diseases (e.g. beta-thalassemia)
or modifier (e.g. sickle cell anemia) [48] but their mech-
anism of action is unclear. Our mechanistic models pro-
vide chains of argumentation for the causal effects of
such rare regulatory variants mediated by increased levels
of amyloid-beta.It is noteworthy that BEL models go far beyond mere
representation of genetic information by including down-
stream molecular entities and biological processes and
pathways. However, BEL lacks a temporal dimension;
the language has not been designed to capture kinetic infor-
mation. Our future strategy to deal with the temporal
dimension of Alzheimer is, to generate models represent-
ing the staging of Alzheimer by capturing the knowledge
available for different stages. A first step toward stage-
specific identification of biomarker candidates has already
been made [49].
We envision that the application of the (qualitative)
knowledge-based model provided in this study to
mechanism-identification can support target identification
in drug discovery and can be further enhanced by the inclu-
sion of quantitative data. This potential has been already
shown using gene expression alterations between
responders and nonresponders to infliximab therapy in ul-
cerative colitis patients where a quantitative causal (BEL)
network analysis led to the identification of a set of strati-
fying genes which were confirmed by their correlation with
the Mayo score, a score used to diagnose patients with
active ulcerative colitis [50].5. Conclusion
Although there are clear benefits of this BEL-based,
model-driven approach to understanding the complex
mechanisms contributing to disease, there are some consid-
erations for future enhancements to our models. First,
given the pace of scientific research, the models need to
be improved by regular update as more data and knowledge
becomes available. Second, the current version of BEL de-
scribes biological interactions qualitatively and in cases
where the same processes happen in both disease and
normal tissue, quantitative information—when available
in the literature—could allow a finer grained comparison
of the diseased and normal state. Last, many studies on
pathophysiology of neurodegenerative diseases like AD
have been carried out in animal models, but it is not clear
how well these findings are in agreement with humans. The
computerization of such biological processes for represen-
tation, analysis, and comparison of interspecies mecha-
nistic details will be a significant step forward in
translational research.Acknowledgments
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1. Systematic review: We have undertaken a compre-
hensive, systematic approach to capture a wide spec-
trum of knowledge about neuron molecular
physiology in the normal state and in the diseased
(Alzheimer’s disease or AD) state. The knowledge
gathered was used to generate two models, a “normal
neuron” model and a “diseased neuron” model
formalizing and representing major mechanisms un-
derlying neuron physiology and its deregulation in
disease.
2. Interpretation: With the knowledge-based modeling
approach outlined in this article we substantially
add to a computable, comprehensive knowledgebase
in AD research. The formalism applied for the
modeling supports not only sharing of knowledge,
but also the identification of new candidate mecha-
nisms underlying AD.
3. Future directions: The models we publish here are
meant to provide the starting material for an ever-
growing knowledgebase on AD that can be reused,
expanded, and improved by the AD research commu-
nity. Future directions will see an extension of the
models toward epidemiological and clinical evi-
dences, and modeling of epigenetics factors.References
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